검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Daunorubicin Hydrochloride (Daunorubicin Hydrochloride) Alliance for Clinical Trials in On…·Acute Myeloid Leukemia 69 trials·t½ 18.5 h |
|---|---|
Overview Program | Daunorubicin Hydrochloride |
Overview Company | Alliance for Clinical Trials in Oncology |
Overview Modality | ADC |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | B Acute Lymphoblastic Leukemia |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeting IL-4/IL-13 signaling |
MoA Biomarker | biomarker candidate and mechanistic hypothesis for anthracycline responsiveness |
PK/PD Half-life | 18.5 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Design and Characterization of Thermosensitive Niosomes as Platforms for Daunorubicin Delivery.. Background/Objectives: The study describes the elaboration and evaluation of thermosensitive niosomes intended for the systemic application of daunorubicin hydrochloride. The attained stimulus sensitivity would determine the release of the chemotherapeutic predominantly at the target site, which ensure… |
Toxicology CRS | Reported |
Clinical OS | 5 |
Clinical Result source | ClinicalTrials.gov NCT04770272 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Daunorubicin Hydrochloride (Daunorubicin Hydrochloride) Alliance for Clinical Trials in On…·Acute Myeloid Leukemia 69 trials·t½ 18.5 h |
|---|---|
Overview Program | Daunorubicin Hydrochloride |
Overview Company | Alliance for Clinical Trials in Oncology |
Overview Modality | ADC |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | B Acute Lymphoblastic Leukemia |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeting IL-4/IL-13 signaling |
MoA Biomarker | biomarker candidate and mechanistic hypothesis for anthracycline responsiveness |
PK/PD Half-life | 18.5 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Design and Characterization of Thermosensitive Niosomes as Platforms for Daunorubicin Delivery.. Background/Objectives: The study describes the elaboration and evaluation of thermosensitive niosomes intended for the systemic application of daunorubicin hydrochloride. The attained stimulus sensitivity would determine the release of the chemotherapeutic predominantly at the target site, which ensure… |
Toxicology CRS | Reported |
Clinical OS | 5 |
Clinical Result source | ClinicalTrials.gov NCT04770272 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교